HUTCHMED (China) Limited
HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastriā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.96
Price+4.62%
$0.66
1Y
Price
Market Cap
$2.702b
Mid
Price/Earnings 3y Avg5y Avg
5.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+0.9%
EBITDA Margin+163.8%
Net Profit Margin-29.6%
Free Cash Flow Margin+0.9%
EBITDA Margin+163.8%
Net Profit Margin-29.6%
Free Cash Flow MarginRevenue
$549.963m
-4.4%
1y CAGR+22.4%
3y CAGR+21.8%
5y CAGREarnings
$458.117m
+1137.5%
1y CAGR+400.9%
3y CAGR+279.4%
5y CAGREPS
$2.60
+1104.6%
1y CAGR+389.7%
3y CAGR+274.3%
5y CAGRBook Value
$1.251b
$1.753b
Assets$501.837m
Liabilities$97.893m
DebtDebt to Assets
5.6%
-12.5x
Debt to EBITDAFree Cash Flow
-$79.013m
-184.8%
1y CAGR-44.3%
3y CAGR-42.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company